ZLAB vs. ARDX, EWTX, DAWN, AKRO, DVAX, MORF, PTGX, KURA, TARO, and RCUS
Should you be buying Zai Lab stock or one of its competitors? The main competitors of Zai Lab include Ardelyx (ARDX), Edgewise Therapeutics (EWTX), Day One Biopharmaceuticals (DAWN), Akero Therapeutics (AKRO), Dynavax Technologies (DVAX), Morphic (MORF), Protagonist Therapeutics (PTGX), Kura Oncology (KURA), Taro Pharmaceutical Industries (TARO), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical preparations" industry.
Ardelyx (NASDAQ:ARDX) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations, profitability and community ranking.
Ardelyx presently has a consensus target price of $12.81, suggesting a potential upside of 46.93%. Zai Lab has a consensus target price of $64.22, suggesting a potential upside of 295.22%. Given Ardelyx's higher probable upside, analysts plainly believe Zai Lab is more favorable than Ardelyx.
58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 5.5% of Ardelyx shares are owned by insiders. Comparatively, 5.2% of Zai Lab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Ardelyx received 299 more outperform votes than Zai Lab when rated by MarketBeat users. Likewise, 67.67% of users gave Ardelyx an outperform vote while only 63.58% of users gave Zai Lab an outperform vote.
In the previous week, Ardelyx had 21 more articles in the media than Zai Lab. MarketBeat recorded 24 mentions for Ardelyx and 3 mentions for Zai Lab. Ardelyx's average media sentiment score of 0.75 beat Zai Lab's score of 0.71 indicating that Zai Lab is being referred to more favorably in the news media.
Ardelyx has a net margin of -41.36% compared to Ardelyx's net margin of -125.46%. Ardelyx's return on equity of -37.07% beat Zai Lab's return on equity.
Ardelyx has higher earnings, but lower revenue than Zai Lab. Ardelyx is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.
Ardelyx has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.
Summary
Ardelyx beats Zai Lab on 13 of the 19 factors compared between the two stocks.
Get Zai Lab News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
